Notably, microglia spatially associated with amyloid plaques exhibited increased expression of TREM2 and ApoE compared to ...

The complement system is one of the immune system’s oldest defense mechanisms and is historically regarded as a liver-derived and serum-active innate immune system that ‘complements’ cell-mediated and ...

Detailed price information for Zentalis Pharmaceuticals Inc (ZNTL-Q) from The Globe and Mail including charting and trades.

EMA committee recommends marketing approval for Novartis oral Fabhalta to treat adults living with C3 glomerulopathy: Basel Monday, March 3, 2025, 10:00 Hrs [IST] Novartis announc ...

an investigational subcutaneously administered anti-APRIL monoclonal antibody that is currently in Phase III development. This press release contains forward-looking statements within the meaning of ...

Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which targets the biological activity of C5a and demonstrates high selectivity towards its target in human blood.

C3.ai's revenue increased by 26%, reaching $98.8 million. Non-GAAP EPS improved significantly to $(0.12), beating the $(0.25) analyst estimate.. The company expanded its strategic partnerships ...

Antibody treatment resulted in modest prolongation of graft survival (mean survival time (MST) = 13 d; n = 7) when compared with untreated MST = 8 d; n = 6) or control-treated groups (hamster IgG ...

What is the immune system? The immune system works to keep germs and other foreign substances out of the body and destroy any that get in. It's made up of a complicated network of cells and organs. It ...

Artificial intelligence (AI) software company C3.ai (NYSE:AI) will be reporting earnings tomorrow after market close. Here’s what investors should know. C3.ai beat analysts’ revenue ...

C3.ai is an artificial intelligence (AI) software company, often compared to Palantir. While C3.ai is experiencing rapid revenue growth, the company's cash burn remains an issue. History shows a ...